2011
DOI: 10.1186/1750-1326-6-86
|View full text |Cite
|
Sign up to set email alerts
|

Resorufin analogs preferentially bind cerebrovascular amyloid: potential use as imaging ligands for cerebral amyloid angiopathy

Abstract: BackgroundCerebral amyloid angiopathy (CAA) is characterized by deposition of fibrillar amyloid β (Aβ) within cerebral vessels. It is commonly seen in the elderly and almost universally present in patients with Alzheimer's Disease (AD). In both patient populations, CAA is an independent risk factor for lobar hemorrhage, ischemic stroke, and dementia. To date, definitive diagnosis of CAA requires obtaining pathological tissues via brain biopsy (which is rarely clinically indicated) or at autopsy. Though amyloid… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
52
0

Year Published

2014
2014
2024
2024

Publication Types

Select...
9
1

Relationship

2
8

Authors

Journals

citations
Cited by 53 publications
(53 citation statements)
references
References 46 publications
(56 reference statements)
1
52
0
Order By: Relevance
“…To explore the potential mechanisms by which anti-ROS therapy reduces CV deficits in aged Tg2576 mice, we visualized CAA and neuritic plaque loads using the congophilic fibrillar amyloid dyes methoxy-X04 (for in vivo imaging of CAA and neuritic plaques) (40), methoxy-X34 (for in situ staining of CAA and neuritic plaques) (40), and resorufin (for in situ staining of CAA alone) (41). Similar to our previous report (13), substantial deposition of CAA and neuritic plaques was noted in 15-mo-old, vehicle-treated Tg2576 mice where CAA deposits had progressed to encompass almost the entire leptomeningeal arteriolar system without interruption ( Fig.…”
Section: Resultsmentioning
confidence: 99%
“…To explore the potential mechanisms by which anti-ROS therapy reduces CV deficits in aged Tg2576 mice, we visualized CAA and neuritic plaque loads using the congophilic fibrillar amyloid dyes methoxy-X04 (for in vivo imaging of CAA and neuritic plaques) (40), methoxy-X34 (for in situ staining of CAA and neuritic plaques) (40), and resorufin (for in situ staining of CAA alone) (41). Similar to our previous report (13), substantial deposition of CAA and neuritic plaques was noted in 15-mo-old, vehicle-treated Tg2576 mice where CAA deposits had progressed to encompass almost the entire leptomeningeal arteriolar system without interruption ( Fig.…”
Section: Resultsmentioning
confidence: 99%
“…In a subset of aged Tg2576 mice (N=4), CAA and neuritic plaque load was quantified post mortem as per our established protocol. 27 Briefly, mice were sacrificed 72 hours post-MCAO, followed by brain extraction, fixation (4% paraformaldehyde), equilibration (30% sucrose), and coronal sectioning (50μm). Brain sections were stained with 1μM resorufin (which selectively stains CAA) and 2μM methoxy-X34 (which stains both CAA and neuritic plaques).…”
Section: Methodsmentioning
confidence: 99%
“…43 Resorufin (a phenoxazine derivative) and multidentate 18 F-polypegylated styrylpyridines showed preferential binding of cerebrovascular Aβ deposits over neuritic plaques in vitro but they have not been shown to cross blood-brain barrier in vivo. 44,45 More recently, 99m…”
Section: Challenges and Future Directionsmentioning
confidence: 99%